SEC Filings

8-K
MEDTRONIC PLC filed this Form 8-K on 12/12/2017
Entire Document
 
Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 8-K
CURRENT REPORT
_____________________________
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2017
_____________________________
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
_____________________________
Ireland
 
1-36820
 
98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
20 On Hatch, Lower Hatch Street, Dublin 2, Ireland
(Address of principal executive offices)
+353 1 438-1700
(Registrant’s telephone number, including area code):
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company     ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan
As reported in Item 5.07 of this report, at the 2017 Annual General Meeting of Shareholders of Medtronic plc, a public limited company organized under the laws of Ireland (the “Company”), shareholders approved the amendment and restatement of the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan (the “Plan”) to increase the authorized number of ordinary shares under the Plan by fifty million (50,000,000).
Certain updates were made to the Plan to reflect changes in the law, accounting rules and current practices, including the following:

Adding EBITDA and operating cash flow to the definition of “Performance Goals”;
Clarifying that, with respect to all awards, dividends or other distributions or dividend equivalents may not be paid until an award is vested;
Providing that withholding obligations may be settled with shares up to the maximum statutory tax rate in the applicable jurisdiction;
Providing that, if shares are withheld at a rate that is higher than the minimum statutory tax rate, only the number of shares withheld at the minimum statutory tax rate will again become available for issuance under the Plan; and
Updating the Irish statutory references in the Plan to ensure consistency with the Irish Companies Act of 2014.

Unless otherwise determined by the Board of Directors, the Plan will be administered by the Compensation Committee (the “Committee”). The Committee, in its discretion, may grant options, share appreciation rights, restricted stock, restricted stock units, other share-based awards and performance awards under the Plan to selected directors, officers, employees and consultants of the Company and its subsidiaries, as designated by the Committee.

The Committee may determine that a performance-based award is intended to be exempt from the limits on deductibility under Section 162(m) of the Internal Revenue Code (the “Code”). In such cases, in order to meet the requirements for that exemption, the goals must be based on one or more of the following criteria set forth in the Plan: sales, net sales, revenue, revenue growth or product revenue growth, operating income (before or after taxes), earnings before interest, taxes, depreciation, and amortization, operating cash flow, return on invested capital, return on capital employed, pre- or after-tax income (before or after allocation or corporate overhead and bonus), net earnings, earnings per share, diluted earnings per share, consolidated earnings before or after taxes (including earnings before some or all of the following: interest, taxes, depreciation and amortization), net income, gross profit, gross margin, year-end cash, debt reductions, book value per share, return on equity, expense management, return on investment, improvements in capital structure, profitability of an identifiable business unit or product, maintenance or improvements of profit margins, stock price, market share, costs, cash flow, working capital, return on assets or net assets, asset turnover, inventory turnover, economic value added (economic profit) or equivalent metrics, comparison with various stock market indices, appreciation in and/or maintenance of share price, reductions in costs, regulatory achievements, implementation, completion or attainment of measurable objectives with respect to research, development, products or projects and recruiting or maintaining personnel, and total shareholder return; each as measured with respect to the Company or one or more subsidiaries, divisions, business units, or business segments of the Company, either in absolute terms or relative to the performance of one or more other companies or an index covering multiple companies.

Subject to adjustment, no Plan participant may be granted (a) options and stock appreciation rights relating to more than 2,000,000 shares under the Plan during any fiscal year and (b) awards other than options or stock appreciation rights relating to more than 2,000,000 shares under the Plan during any fiscal year. In addition, the maximum dollar value that may be paid in any fiscal year to any participant in performance-based awards that are denominated in cash and that are intended to be exempt from the limits on deductibility under Section 162(m) of the Code will be $20,000,000 for the Company’s Chief Executive Officer and $10,000,000 for each other participant, including any amounts earned during such fiscal year and deferred.

The material terms of the Plan are described in additional detail in the Company's revised definitive proxy statement for the 2017 Annual General Meeting, which was filed with the Securities and Exchange Commission on October 11, 2017, which description is incorporated herein by reference. A copy of the Plan is attached hereto as Exhibit 10.1 and is incorporated herein by reference and constitutes a part of this report.






Item 5.07 Submission of Matters to a Vote of Security Holders.
On December 8, 2017, the Company held its 2017 Annual General Meeting of Shareholders in order to: (1) elect twelve directors, each to hold office until the 2018 Annual General Meeting of the Company and until his or her successor is elected; (2) ratify, in a non-binding vote, the re-appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2018 and authorize, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration; (3) approve, in a non-binding advisory vote, named executive officer compensation; and (4) approve the amendment and restatement of the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan.

At the close of business on October 10, 2017, the record date of the Annual General Meeting, 1,353,214,320 Company ordinary shares were outstanding and entitled to vote. The holders of a total of 1,166,669,952 ordinary shares were present at the Annual General Meeting, either in person or by proxy, which total was not less than a majority of the issued and outstanding ordinary shares entitled to vote and thus constituted a quorum.

The final voting results and the votes used to determine the results for each proposal are set forth below:
1.
The shareholders elected each of the twelve nominees to the Board of Directors, to hold office until the 2018 Annual General Meeting of the Company and until his or her successor is elected, as follows:

 
 
For
 
For (Percent of Votes Cast)
 
Against
 
Against (Percent of Votes Cast)
 
Abstain
 
Broker Non-Vote
Richard H. Anderson
 
1,021,793,217
 
 
96.5429
 
 
36,589,755
 
 
3.4571
 
 
2,689,807
 
 
105,597,173
 
Craig Arnold
 
1,035,899,722
 
 
97.7074
 
 
24,306,096
 
 
2.2926
 
 
866,961
 
 
105,597,173
 
Scott C. Donnelly
 
1,037,152,753
 
 
97.8232
 
 
23,079,097
 
 
2.1768
 
 
840,929
 
 
105,597,173
 
Randall Hogan, III
 
1,043,349,429
 
 
98.4096
 
 
16,862,064
 
 
1.5904
 
 
861,286
 
 
105,597,173
 
Omar Ishrak
 
1,022,487,043
 
 
96.5518
 
 
36,516,353
 
 
3.4482
 
 
2,069,383
 
 
105,597,173
 
Shirley Ann Jackson, Ph.D.
 
1,036,573,607
 
 
97.7645
 
 
23,702,800
 
 
2.2355
 
 
796,372
 
 
105,597,173
 
Michael O. Leavitt
 
1,050,350,857
 
 
99.0640
 
 
9,924,179
 
 
0.9360
 
 
797,743
 
 
105,597,173
 
James T. Lenehan
 
1,054,892,327
 
 
99.4918
 
 
5,388,467
 
 
0.5082
 
 
791,985
 
 
105,597,173
 
Elizabeth Nabel, M.D.
 
1,055,311,908
 
 
99.5292
 
 
4,991,999
 
 
0.4708
 
 
768,872
 
 
105,597,173
 
Denise M. O’Leary
 
1,045,416,998
 
 
98.6006
 
 
14,836,932
 
 
1.3994
 
 
818,849
 
 
105,597,173
 
Kendall J. Powell
 
977,434,514
 
 
92.1888
 
 
82,817,956
 
 
7.8112
 
 
820,309
 
 
105,597,173
 
Robert C. Pozen
 
1,046,057,404
 
 
98.8201
 
 
12,489,358
 
 
1.1799
 
 
2,526,017
 
 
105,597,173
 

2.
The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2018 and authorized, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration.
 
 
Votes
 
Percent of Votes Cast
For
 
1,144,267,987
 
98.2872
Against
 
19,940,528
 
1.7128
Abstain
 
2,461,437
 
N/A
Broker Non-Vote
 
N/A
 
N/A








3.
The shareholders approved, on a non-binding advisory basis, the compensation awarded to the Company’s named executive officers.
 
 
Votes
 
Percent of Votes Cast
For
 
991,141,552
 
94.0442
Against
 
62,768,866
 
5.9558
Abstain
 
7,162,361
 
N/A
Broker Non-Vote
 
105,597,173
 
N/A

4.
The shareholders approved the amendment and restatement of the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan.
 
 
Votes
 
Percent of Votes Cast
For
 
999,504,176
 
94.6067
Against
 
56,979,448
 
5.3933
Abstain
 
4,589,155
 
N/A
Broker Non-Vote
 
105,597,173
 
N/A


Item 9.01 Financial Statements and Exhibits
Exhibit
Number
 
Description
 
 
10.1
 
Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan
- 2 -






SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
 
MEDTRONIC PUBLIC LIMITED COMPANY
 
 
 
 
 
 
By
/s/ Bradley E. Lerman
Date: December 11, 2017
 
 
Bradley E. Lerman
 
 
 
Senior Vice President, General Counsel and Corporate Secretary





Exhibit Index




X